ArticleBMC surgery2022
Conversion surgery for stage IV gastric cancer: a multicenter retrospective study.
Article in BMC surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.International journal of cancer · 2025Trial
- From Control to Conversion: Optimizing Systemic Therapy for Curative-Intent Conversion Surgery in Metastatic Gastric Cancer.Journal of gastric cancer · 2026Review
- Clinical stratification utility of HER2, PD-L1, MSI/MMR, and CLDN18.2 in conversion therapy for gastric cancer: narrative review.Frontiers in oncology · 2026Review
- Conversion Surgery for Advanced Gastric Cancer with Para-Aortic Lymph Node Metastases Following Treatment with Capecitabine, Oxaliplatin, and Pembrolizumab: A Case Report.Surgical case reports · 2026Article
- Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Article
- Successful Conversion Surgery Following S-1 Plus Oxaliplatin Combined with Nivolumab Therapy for a Preoperatively Diagnosed Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report.Surgical case reports · 2025Article
- Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.Journal of gastric cancer · 2025Review
- Conversion Surgery via Laparoscopic Gastrectomy and Hepatectomy for Advanced Gastric Neuroendocrine Carcinoma with Extensive Liver Metastases: A Case Report.Surgical case reports · 2025Article
- Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Article
- Prognostic factors of conversion surgery for stage IV gastric cancer: A multi-institutional retrospective analysis.Annals of gastroenterological surgery · 2024Article
- Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report.Frontiers in oncology · 2024Article
- Advances, breakthroughs, and challenges in gastric cancer surgery.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Conversion surgery for advanced jejunal adenocarcinoma with multiple peritoneal metastases: a case report.Surgical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundRecent improvements in systemic chemotherapy have provided an opportunity for patients with stage IV gastric cancer (GC) to undergo conversion surgery (CS). The aim of this study was to evaluate the long-term outcomes of patients who underwent CS and to elucidate the prognostic factors for CS in stage IV GC.
methodsA total of 79 patients who underwent CS with the aim of R0 resection for stage IV GC at six institutions from January 2008 to July 2019 were enrolled. We retrospectively reviewed the clinicopathological data and prognosis.
resultsOf the 79 patients, 23 (31.1%) had initially resectable disease (IR) before chemotherapy, defined as positive for cancer on peritoneal cytology (CY1), resectable hepatic metastasis, or para-aortic lymph node No. 16a2/b1 metastasis. Of the 56 remaining patients with primary unresectable disease, 39 had peritoneal dissemination. R0 resection was accomplished in 63 patients (79.7%). The 3-year OS rates for patients with IR and unresectable disease were 78.3% and 44.5%, respectively. Multivariate analysis showed that IR (P = 0.014) and R0 (P = 0.014) were statistically significant independent prognostic factors for favorable OS. Among patients with peritoneal dissemination alone, OS was significantly better for patients with R0 resection than for patients with R1/2 resection, with the 3-year OS rates of 65.5% and 23.1%, respectively (P = 0.011).
conclusionsCS is a treatment option for selected patients with stage IV GC. Patients with IR and patients who achieve R0 resection may obtain a survival benefit from CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.